CD38 and neoplasm: This monoclonal antibody has demonstrated its killing activity against CD38-expressing tumor cells, inducing antibody dependent cellular cytotoxicity (ADCC), complement–dependent cytotoxicity (CDC), macrophage-mediated phagocytosis and cell lysis in CD38+ myeloid derived suppressor cells and Tregs [19,20].